Combining Isotopic Tracer Techniques to Increase Efficiency of Clinical Pharmacokinetic Trials in Oncology

Area of Science:

• Pharmacology
• Clinical Drug Development
• Mass Spectrometry

Background:

• Drug development in oncology faces challenges with small patient populations, limiting pharmacokinetic studies.
• Current clinical trial designs may not fully leverage available resources for pharmacokinetic assessments.
• Advancements in analytical techniques like liquid chromatography-tandem mass spectrometry enable richer data collection.

Purpose of the Study:

• To advocate for a hybrid trial approach to improve the quality and efficiency of pharmacokinetic assessments in oncology drug development.
• To address the limitations of small patient populations in answering key clinical pharmacology questions.
• To propose a method for obtaining comprehensive pharmacokinetic data within the drug development timeline.

Main Methods:

• Utilizing isotopic tracer techniques, specifically radiolabeled and stable isotopically labeled drugs.
• Administering both types of labeled drugs to patients within a single clinical trial.
• Leveraging high-sensitivity liquid chromatography-tandem mass spectrometry for data acquisition.

Main Results:

• The proposed hybrid approach allows for the simultaneous assessment of absolute bioavailability and absorption, distribution, metabolism, and excretion (ADME).
• This method generates high-quality, rich pharmacokinetic data from a single experimental setting.
• It offers a more efficient use of limited patient populations and resources in clinical trials.

Conclusions:

• A hybrid trial design combining radiolabeled and stable isotopically labeled drugs is a valuable strategy for oncology drug development.
• This approach enhances the efficiency and quality of pharmacokinetic studies, addressing challenges posed by small patient cohorts.
• The integration of advanced analytical techniques supports the generation of comprehensive drug disposition data in a single trial.